BioNTech SE generates revenue through three primary mechanisms: collaboration profit-sharing on commercialized products, direct product sales in designated territories, and research collaboration fees with pharmaceutical partners. The dominant revenue stream remains the Pfizer collaboration on Comirnaty, the COVID-19 mRNA vaccine, which accounted for 73% of total 2024 revenues ($2.2 billion of $3.0 billion total). Under this collaboration structure, Pfizer handles commercialization, manufacturing scale-up, and distribution in most global territories, while BioNTech receives a share of gross profits. The exact profit-sharing ratio is not publicly disclosed but is understood to be roughly equal based on industry standard 50/50 splits for co-developed vaccines. This collaboration generated $15.0 billion for BioNTech in 2022, $3.6 billion in 2023, and $2.2 billion in 2024, demonstrating the steep demand cliff as COVID-19 transitioned from pandemic to endemic status. BioNTech's direct sales territory—primarily Germany and Turkey—contributed additional revenue, though specific territorial breakdowns are consolidated within the overall collaboration reporting. The second revenue stream comprises pandemic preparedness contracts with governmental authorities, most notably the German Federal Ministry of Health, which contributed $764.1 million (25% of total 2024 revenues) through contracts for strategic vaccine reserves and variant-adapted vaccine development. This stream is inherently lumpy and dependent on public health policy decisions rather than commercial market dynamics. Other customers contributed a mere $41.9 million (2% of revenues), underscoring the extreme revenue concentration risk. The gross margin on revenues was exceptionally high at 90.2% in 2024 ($2.2 billion gross profit on $2.4 billion BioNTech SE standalone revenues), though this is somewhat misleading because the cost of sales primarily reflects Pfizer's profit share rather than traditional manufacturing costs. On a consolidated group basis, cost of sales was $590.0 million against $3.0 billion in revenues, yielding a gross margin of 80.3%. The R&D expense burden is the defining feature of BioNTech's current business model. In 2024, the company spent $2.5 billion on R&D—82% of total revenues—making it one of the most R&D-intensive public biotechnology companies globally. This spending breaks down into $257.2 million for COVID-19 vaccine development (down 25% from 2023) and $2.2 billion for non-COVID programs (up 37%), with the oncology pipeline consuming the vast majority. The company has guided R&D expenses to remain elevated as it advances multiple programs through late-stage clinical trials. SG&A expenses totaled $652.9 million in 2024, up 7% from 2023, driven by commercial IT platform investments and headcount growth. The net result is a cash-burn business model where current revenues from declining COVID vaccine sales fund the development of future oncology products. BioNTech's cash and cash equivalents plus security investments stood at $19.0 billion as of December 31, 2024, providing substantial but not infinite runway. At the 2024 burn rate of approximately $1.2 billion in net losses plus capital expenditures, this represents roughly 15 years of funding, though the company has signaled intentions to increase R&D spending as oncology trials scale. The company expects 2025 total revenues between $1.9 billion and $2.4 billion, implying further contraction. The business model's viability hinges on successful oncology product launches beginning in 2026, which would transform revenue from collaboration-dependent, government-contract-lumpy streams into recurring pharmaceutical product sales with higher margins and greater predictability. The BNT327 bispecific antibody, if approved, would compete in the $40+ billion checkpoint inhibitor market. The mRNA cancer immunotherapy platform, including individualized neoantigen vaccines, represents a potentially disruptive approach to adjuvant cancer treatment with limited direct competition. BioNTech's manufacturing infrastructure in Marburg, Germany, and its newly acquired Biotheus facility in China, provide GMP capabilities that could support commercial-scale production of biologics and mRNA products. The company has also established a collaboration with Duality Biologics for ADC manufacturing and maintains partnerships with Genentech/Roche, Regeneron, OncoC4, and others that provide non-dilutive funding for specific programs. The financial architecture is therefore one of deliberate, aggressive reinvestment: using declining but still substantial COVID vaccine cash flows to fund a multi-year, multi-billion-euro oncology development campaign with the goal of achieving sustainable product revenues before the cash reserves deplete.